Benzinga | Mar 8, 2021 08:40AM EST

Cara Therapeutics/Vifor Pharma's Korsuva US Application In Pruritus Accepted For Review

* The FDA has accepted Cara Therapeutics Inc's (NASDAQ: CARA) and its partner's Vifor Pharma (OTCMKT: GNHAF) marketing application for Korsuva (difelikefalin) solution for injection for pruritus (or itch) in hemodialysis patients.

* Under priority review status, the target action date is August 23.

* The agency also stated that currently, it is not planning to hold an advisory committee for the application.

* If approved, Korsuva injection would be the first therapy for the treatment of pruritus in hemodialysis patients.

* Price Action: CARA shares are up 8.40% at $18.09 in the premarket trading on the last check Monday.